Myelodysplastic and myeloproliferative disorders are rare in childhood and there is no widely accepted system for their diagnosis and classification. We propose minimal diagnostic criteria and a simple classification scheme which, while based on accepted morphological features and conforming with the recent suggestions of the WHO, allows for the special problems of myelodysplastic diseases in children. The classification recognizes three major diagnostic groups: (1) juvenile myelomonocytic leukemia (JMML), previously named chronic myelomonocytic leukemia (CMML) or juvenile chronic myeloid leukemia (JCML); (2) myeloid leukemia of Down syndrome, a disease with distinct clinical and biological features, encompassing both MDS and AML occurring in Down syndrome; and (3) MDS occurring both de novo and as a complication of previous therapy or pre-existing bone marrow disorder (secondary MDS). The main subtypes of MDS are refractory cytopenia (RC) and refractory anemia with excess of blasts (RAEB). It is suggested retaining the subtype of RAEB-T with 20-30% blasts in the marrow until more data are available. Cytogenetics and serial assessments of the patients are essential adjuncts to morphology both in diagnosis and classification.
Background
Myelodysplastic syndrome (MDS) in children and adolescents has hitherto received sparse attention in the pediatric literature and, despite recent attempts, [1] [2] [3] [4] [5] [6] there has been no generally agreed system of classification or diagnosis. Recommendations for the classification of childhood cancer do not even mention MDS. 7 The lack of a generally accepted classification may have contributed to underdiagnosis of MDS in childhood. However, both MDS and juvenile myelomonocytic leukemia (JMML) are uncommon in children, each constituting less than 5% of all hematological malignancies ( Table 1) .
The authors met during the SIOP meeting in Montreal, September 1999 and the 2nd MDS symposium in Denmark, May 2000. Consensus was achieved both on minimal diagnostic criteria for MDS in childhood (Table 2 ) and on a proposal for the classification of pediatric myelodysplastic and myeloproliferative diseases (Table 3) . Excluding Down syndrome (DS). b PV, polycythemia vera; ET, essential thrombocythemia.
Table 2
Minimal diagnostic criteria for MDS At least two of the following:
• Sustained unexplained cytopenia (neutropenia, thrombocytopenia, or anemia) • At least bilineage morphologic myelodysplasia • Acquired clonal cytogenetic abnormality in hematopoietic cells • Increased blasts (Ն5%) 
FAB and WHO classifications
The French-American-British (FAB) cooperative group produced the first systematic attempt of classification. MDS was divided into five subgroups: refractory anemia (RA), RA with ringed sideroblasts (RARS), RA with excess of blasts (RAEB), RAEB in transformation (RAEB-T), and chronic myelomonocytic leukemia (CMML). 8, 9 Distinction between the subtypes of MDS was largely based on the proportion of blasts in the peripheral blood (PB) and bone marrow (BM) and the degree of monocytosis in the blood. The BM blast count has a major influence on prognosis in MDS. 10 The FAB classification became widely accepted among hematologists and has been an important tool of communication about this group of clinically heterogeneous disorders. The recent classification of hematologic malignancies from the WHO 11 incorporates both morphology and genetic changes. The threshold for distinguishing acute myeloid leukemia (AML) from MDS was lowered from 30% to 20% blasts in the BM.
Both the FAB and the WHO proposals were based on review of adult cases. The WHO classifications recognizes JMML as a separate entity. There are many differences between MDS in children and adults, eg RARS is exceedingly rare in children, [1] [2] [3] [4] [5] [6] deletion 5q has occasionally been observed in children [12] [13] [14] but the 5q− syndrome characterized by 5q− as the sole abnormality, BM blasts Ͻ5%, normal or elevated platelet count, an indolent course and long survival has not been described in children. Constitutional abnormalities are often observed in children with MDS and JMML. [1] [2] [3] [4] [5] [6] The unique features of Down syndrome is not appropriately addressed in the WHO classification. There are no data to indicate whether the blast threshold of 20% is better than the traditional 30% to distinguish MDS from AML in children. The present amendments address the specific diagnostic problems in children.
Current approach to the classification of childhood MDS
The participants at the two international meetings to discuss pediatric MDS agreed on the need for a classification addressing the specific diagnostic and therapeutic problems in children.
The new classification proposal comprises three major diagnostic categories (Table 3) : (1) a group of myelodysplastic/myeloproliferative disorders with JMML as the most common disorder of this category; (2) myeloid leukemia of Down syndrome (DS) including both MDS and AML in children with DS; (3) MDS including the subtypes refractory cytopenia (RC), RAEB, and RAEB-T.
Juvenile myelomonocytic leukemia (JMML) and other myelodysplastic/myeloproliferative disorders
JMML is a unique pediatric disorder previously referred to as juvenile chronic myeloid leukemia (JCML) or as CMML referring to a pediatric equivalent of CMML as defined by the FAB group. JMML is a bridging disorder between MDS and myeloproliferative diseases 15 and included into the new WHO category of myelodysplastic/myeloproliferative disorders.
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Diagnostic criteria for JMML have been published 16 ( Table   Table 4 Diagnostic guidelines for JMML adopted from Ref. 4). The blood film appearance is characteristic and often more helpful than the BM smear. Patients with JMML may have up to 20% blasts in the blood, the BM blast count at diagnosis is usually below 20%. JMML includes patients with monosomy 7 previously considered to represent a distinct hematologic disorder described as the monosomy 7 syndrome. 17 There are no major clinical differences between JMML in children with and without monosomy 7.
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The term CMML is included in the classification but is reserved for cases secondary to previous chemotherapy.
BCR-ABL-negative chronic myeloid leukemia is extremely rare in children and most cases are probably JMML. When BCR-ABL-negative CML is diagnosed it should be included in the group of myelodysplastic/myeloproliferative disorders.
Myeloid leukemia of Down syndrome
Individuals with Down syndrome (DS) have a more than 50-fold increased risk of leukemia during the first 5 years of life with about half the leukemias being myeloid. 20 Furthermore, a myeloproliferative disorder indistinguishable from leukemia may occur in newborns with DS.
Transient abnormal myelopoiesis
Newborns with DS may show a clinical and morphological picture indistinguishable from AML. The blast cells often have cell surface antigens characteristic of megakaryoblasts. 21 The condition is referred to as transient abnormal myelopoiesis (TAM), transient leukemic reaction, transient myeloproliferative disorder or transient leukemia. 21 Life-threatening complications may occur in a few patients, but spontaneous remission appears in the majority within 3 months. AML develops 1-3 years later in about one quarter of the children. 21 It is uncertain whether TAM should be considered a malignant disease.
Myeloid leukemia in Down syndrome
Myeloid leukemia occurring in children with DS outside the neonatal period is often characterized by blast cells with morphologic and antigen features of megakaryoblasts, although other morphological variants do occur. Many patients have a relatively indolent course characterized by a period of thrombocytopenia and dysplasia with less than 30% blasts in the marrow. In contrast to TAM, MDS/AML in older children is fatal if untreated but responds well to AML treatment with a very favorable prognosis. [22] [23] [24] There are many distinctive features confirming the biological differences between MDS/AML-M7 in children with and without DS. 24 Unlike de novo patients there are no biological differences between MDS and AML in DS and the distinction between MDS and AML has no prognostic or therapeutic consequences. The type of leukemia seems to be unique to children with DS and should be classified and reported separately. The unifying term myeloid leukemia of DS may most appropriately describe what previously was called MDS and AML in children with DS.
Myeloid leukemia in older DS children (3 years or older) behaves more like AML in patients without DS and has a poorer prognosis. 25 Such patients may present as 'true de novo' AML 26 not fulfilling the criteria for myeloid leukemia of DS.
Myelodysplastic syndrome
The two major diagnostic challenges are to distinguish MDS with a low blast count from aplastic anemia (AA) and other non-clonal BM disorders and to differentiate MDS with excess of blasts from AML. The traditional classification has been based on morphology but a number of additional factors need to be considered.
Refractory cytopenia
Myelodysplasia may occur in the BM in a variety of disorders of very different etiologies, eg infection, 27 drug therapy 28 and chronic disease. 29 Non-clonal disorders with dysplastic features, eg mitochondrial disorders like Pearson syndrome, should not be considered as MDS.
It may be difficult to diagnose MDS in children who have a low blast cell count and no clonal marker. We suggest that the minimal diagnostic criteria listed in Table 2 are adhered to in this context. Although the WHO classification has a definition of 'minimal' dysplasia being at least 10% of the cell lineage, we are reluctant to utilize this specific criteria for children where marked dysplasia may be observed in reactive conditions as well as discrete dysplasia in MDS.
Persistent cytopenia with hypo-or hypercellular BM and a blast count below 5% may indicate MDS when infectious diseases, metabolic disorders and other causes of cytopenia and dysplasia have been ruled out. Anemia is not always present in MDS, hemoglobin Ͻ10 g/dl in 56% of patients with RC, whereas elevated MCV is observed in 75% (Niemeyer, personal communication May 2002) . It is suggested that refractory cytopenia (RC) may be a more appropriate term than refractory anemia since anemia is not always present.
Since hematopoiesis is often dysplastic in patients with congenital BM failure disorders, we suggest diagnosing MDS in these patients only if the BM blast count is increased, a persistLeukemia ent clonal chromosomal abnormality is present or hypercellularity in the BM develops in the presence of persistent PB cytopenia. RARS is extremely rare in children; five studies reporting on 313 children with MDS included only two cases of RARS.
1,2,4-6 There are no data to document whether patients with RARS share distinctive clinical features. We suggest that RARS is included in the category of refractory cytopenia. The finding of sideroblastic anemia should prompt investigation for possible mitochondrial cytopathy or disorders of heme synthesis. 30 Differentiating hypoplastic MDS from AA may be very challenging. A trephine biopsy is mandatory in the evaluation of a child with suspected AA or MDS. A careful search for morphologic characteristics at diagnosis will often establish a distinction between the two entities. [31] [32] [33] The biopsy in hypoplastic MDS shows sparsely scattered granulopoietic cells, patchy islands of immature erythropoiesis and in most cases decreased megakaryopoiesis and in some micromegakaryocytes. 33 Clonal hematopoiesis is strongly indicative of MDS, but may occasionally be seen in AA 34, 35 and particularly in FA. 36 Overexpression of p53 is suggestive of MDS.
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Refractory anemia with excess of blasts (RAEB)
RAEB is defined by a BM blast count between 5 and 20%. Auer rods are no longer a discriminator for classification. The international prognostic scoring system (IPSS) for MDS in adults has recommended subdivision of RAEB, according to the BM blasts, 10 into BM blasts 5-10% and 11-20%. This scheme warrants further investigation in pediatrics.
Patients with recurrent cytogenetic abnormalities typically associated with AML, eg t(15;17) (PML/RAR␣), t(8;21) (AML1/ETO), inv(16)(CBF␤/MYH11), t(9;11) (MLL/AF9), should be diagnosed and treated as AML regardless of the blast count. 38 It is recommended performing both cytogenetic and appropriate molecular biologic-based testing for the above mentioned aberrations.
Refractory anemia with excess of blasts in transformation (RAEB-T)
MDS and true de novo (TDN)-AML display significant differences in pathogenesis and natural course. 39 The cytogenetic differences predicting response to therapy in MDS/AML may reflect the underlying biologic nature of the disease. TDN-AML is a chemo-sensitive disease characterized by specific recurring translocations, whereas MDS and secondary AML is characterized by numerical chromosomal abnormalities and typically resistant to chemotherapy. Patients with adverse cytogenetics have a poor response to therapy irrespective of the proportion of blasts in the BM and have been described as MDS-related AML (MDR-AML) Monosomy 7 is the most common acquired abnormality in children with MDS. 1, 4 Children with monosomy 7 and MDS have an outcome similar to MDS patients without monosomy 7 whereas patients diagnosed as AML with monosomy 7 have a lower response rate to chemotherapy 19, 40 and a higher relapse rate 41 compared with AML without −7. Monosomy 7 may be regarded as a marker of a MDS-like disease.
The recent WHO classification 11 suggested abolition of the category of RAEB-T including most of these patients as AML with multilineage dysplasia. The cut off point for diagnosis of AML was lowered from the traditional 30% to 20% blast cells.
This distinction is clearly an arbitrary one and there must in practice be a continuum between RAEB and AML. There are no data to indicate whether a 20% blast cell cut off is useful in pediatrics. A recent British study suggested a better outcome following AML therapy in patients with RAEB-T compared with RAEB, 42 however, this was not found in a recent American study. 40 The experiences from EWOG-MDS showed poor response to chemotherapy in RAEB-T and no benefit from chemotherapy before SCT. 43 Until more data are available we suggest maintaining the RAEB-T category.
It is important to recognize that any threshold of blast percentage to separate MDS from AML is a surrogate marker for the underlying biologic behavior of the disease. In patients with ambiguous blast count a more clinical relevant approach may be based upon clinical features, cytogenetics and serial assessment of the BM rather than to predict clinical behavior from a single examination. Significant hepatosplenomegaly and increased WBC are suggestive of AML. In patients presenting with a BM blast percentage of 20-30% and no clinical or cytogenetic changes characteristic of MDS or TDN-AML it is recommended to repeat the BM examination 2 weeks later. If the blast count has increased to above 30% the patient most likely has TDN-AML. If the blast count is stable an arbitrary period of 4 weeks is suggested before establishing a diagnosis of RAEB-T.
It should be emphasized that the vast majority of children with de novo myeloid leukemia present with frank AML. De novo MDS presenting as RC or RAEB is rarer than AML. Only a few patients present with a disease in the borderline zone between MDS and AML.
Secondary MDS
MDS may occur secondary to a constitutional or acquired abnormality (Table 5) . Myeloid neoplasias in patients with predisposing conditions almost always share the biologic characteristics of MDS regardless of the presenting blast count. It is essential to note whether MDS is primary or secondary, as preceding events may affect treatment decisions and alter outcome and may also provide insight into the pathogenesis of MDS.
The natural history and the therapy are different when MDS 44 and those patients should be reported separately. There are no solid data documenting whether MDS occurring in patients with constitutional abnormalities other than Down syndrome and Fanconi anemia differ from MDS in other children. We suggest that such patients should be included in series of MDS and the type and frequency of constitutional abnormalities should be reported. Therapy-related MDS and MDS following AA should be diagnosed according to the MDS guidelines but reported separately.
Scoring systems
There have been few systematic attempts to define a prognostic score in pediatric MDS. Passmore et al 1 related outcome to fetal hemoglobin, platelet count at diagnosis and cytogenetic complexity, but the score has not been applied prospectively to any other series of patients.
The international prognostic scoring system (IPSS) for MDS in adults 10 seems to have limited prognostic impact in children. 6, 45 More recently, the Toronto group proposed a descriptive scoring system designed to assess children with MDS according to category, cytology and cytogenetics (CCC). 46 The system excluded JMML but included Down syndrome. The cytology subdivides both RC and RAEB into three subgroups based upon dysplasia. The system gives no guidelines of how to differentiate MDS from AA or AML and does not provide any minimal diagnostic criteria. The system records associated abnormalities and cytogenetics as in the present proposal. The main differences between the two systems are the lack of recognition of myeloid leukemia in DS as a unique entity independent of morphology and the dysplasia dependent subdivision of RC and RAEB by the CCC system. 46 Whether the system will provide useful information remains to be seen.
Perspectives
The present classification emphasizes the subtypes of MDS found in children, eliminating adult subtypes that are rare or unseen. The classification recommends recording of pre-existent related conditions, whether congenital, acquired, or iatrogenic.
The proposal for classification reflects our present knowledge and concepts. Even the best classification will face borderline cases difficult to fit into the classification. Refinements in immunologic, cytogenetic, and molecular typing are expected to provide additional information related to the underlying biologic processes and lead to a more clinically relevant stratification of the patients.
